The most powerful shift in clinical research this year:Bringing the clinic to the patient is no longer optional; it's essential for patient enrollment and retention. 2025 proved that sponsors don't...
Read More
Why Diversity in Clinical Trials Remains a Critical Gap Diversity in clinical trials is vital to ensure treatments are safe for everyone. Clinical trial participants come from all backgrounds,...
Read More
Why the Model Matters (Virtual vs. Hybrid With Onsite/Mobile Hubs) Traditional clinical trials often face challenges recruiting participants from diverse backgrounds because there can be barriers...
Read More
When the enrolled population in a study doesn’t reflect how patients are actually treated, clinical trial demographics that look statistically sound on paper can lead to challenges with labeling,...
Read More
One of the most overlooked challenges in clinical research is the travel distance required of participants. According to the American Society of Clinical Oncology (ASCO), over half of oncology trial...
Read More
Why Retention Matters More Than Ever GLP-1 programs often include extended ocular safety follow-up (e.g., 24–36 months). Sustained retention preserves statistical power and reduces bias; across...
Read More
How sponsors keep patient enrollment moving and avoid ocular assessment bottlenecks When recruitment outpaces assessment capacity, timelines slip, and qualified participants disengage. Traditional,...
Read More
In today’s funding environment, sponsors cannot afford preventable rework on ocular endpoints. Regulators are closely examining a potential link between GLP-1 receptor agonists and non-arteritic...
Read More